title: Uraemic pruritus and exposure to di(2-ethylhexyl) phthalate (DEHP) in haemodialysis patients.
abstract: Uraemic pruritus is a frequent and disabling symptom in patients on dialysis. The pathogenesis of uraemic pruritus is nevertheless still obscure. We investigated whether di(2-ethylhexyl)phthalate (DEHP), the most commonly used plasticizer in polyvinylchloride (PVC) haemodialysis tubings, is a possible pathogenetic factor in uraemic pruritus. Serum concentrations of DEHP and its major derivatives mono-(2-ethylhexyl)phthalate (MEHP), 2-ethylhexanol (2-EH) and phthalic acid (PA) were determined in uraemic patients before and after a haemodialysis session and compared with the occurrence and intensity of pruritus in these patients. Twenty-one patients on regular haemodialysis for at least 6 months were examined. The severity of uraemic pruritus was assessed using a standard questionnaire (pruritus score). The quantitative analysis of DEHP and its derivatives was carried out by GC/selected ion monitoring mass spectrometry. Fourteen out of 21 patients (66%) complained about uraemic pruritus to a variable degree. The post-dialysis serum concentrations of DEHP, MEHP and 2-EH were significantly higher than the corresponding pre-dialysis values, whereas the post-dialysis concentrations of PA (0.122 +/- 0.078 microgram/microliter) were significantly lower than pre-dialysis levels (0.194 +/- 0.101 microgram/microliter, P = 0.00068). Neither pre- nor post-dialysis serum concentrations of DEHP, MEHP, PA or 2-EH were correlated with the severity of uraemic pruritus. Additionally, serum concentrations of DEHP and its metabolites did not differ significantly in patients with and without pruritus. These findings suggest that patients on haemodialysis are regularly exposed to considerable amounts of DEHP and metabolites. Phthalic acid, one of the presumed end products of DEHP metabolism, might be eliminated at least in part by haemodialysis. The exposition to DEHP and metabolites during haemodialysis, as assessed by measuring serum concentrations, bears no immediate relation to the occurrence or intensity of uraemic pruritus.
authors.affiliation: Robert-Bosch-Krankenhaus, Department of Internal Medicine, Stuttgart, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Mettang
authors.forename: S
authors.initials: S
authors.lastname: Thomas
authors.forename: T
authors.initials: T
authors.lastname: Kiefer
authors.forename: F P
authors.initials: FP
authors.lastname: Fischer
authors.forename: U
authors.initials: U
authors.lastname: Kuhlmann
authors.forename: R
authors.initials: R
authors.lastname: Wodarz
authors.forename: A W
authors.initials: AW
authors.lastname: Rettenmeier
mesh_terms: D000328:Adult; D004051:Diethylhexyl Phthalate / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000032:analysis; D004952:Esters / Q000097:blood; D000441:Hexanols / Q000097:blood; D006801:Humans; D010795:Phthalic Acids / Q000097:blood; D010968:Plasticizers / Q000032:analysis; D011537:Pruritus / Q000139:chemically induced / Q000209:etiology*; D006435:Renal Dialysis / Q000009:adverse effects*; D014511:Uremia / Q000150:complications
chemical_list: D004952:Esters; D000441:Hexanols; D010795:Phthalic Acids; D010968:Plasticizers; C032279:phthalic acid; D004051:Diethylhexyl Phthalate; C016599:mono-(2-ethylhexyl)phthalate; C034017:2-ethylhexanol